Overall survival with tafasitamab + lenalidomide (LEN) vs routinely administered therapies for ASCT-ineligible relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Outcomes from the observational RE-MIND2 study Meeting Abstract

  

Authors:	Nowakowski, G. S.; Yoon, D. H.; Mondello, P.; Joffe, E.; Peters, A.; Fleury, I.; Greil, R.; Ku, M.; Marks, R.; Kim, K.; Zinzani, P. L.; Trotman, J.; Huang, D.; Waltl, E. E.; Winderlich, M.; Ambarkhane, S.; Hess, G.; Salles, G.
Abstract Title:	Overall survival with tafasitamab + lenalidomide (LEN) vs routinely administered therapies for ASCT-ineligible relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Outcomes from the observational RE-MIND2 study
Meeting Title:	9th Annual Meeting of the Society of Hematologic Oncology (SOHO)
Keywords:	monoclonal antibody; lymphoma; dlbcl; cd19; real-world evidence; abcl
Journal Title:	Clinical Lymphoma, Myeloma and Leukemia
Volume:	21
Issue:	Suppl. 1
Meeting Dates:	2021 Sep 8-11
Meeting Location:	Virtual event
ISSN:	2152-2650
Publisher:	Elsevier Inc.
Date Published:	2021-09-01
Start Page:	S392
End Page:	S393
Language:	English
ACCESSION:	WOS:000691910500329
PROVIDER:	wos
DOI:	10.1016/s2152-2650(21)01891-7
Notes:	Meeting Abstract: ABCL-346 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/187710